Femme Harinck
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Femme Harinck has a total of 81 co-authors. Here are the top co-authors by number of shared publications:
- Jan-Werner Poley
Maastricht University Medical Center, The Netherlands
11 shared publications - Marco J. Bruno
Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands
11 shared publications - Paul Fockens
Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, Netherlands
11 shared publications Anja Wagner
10 shared publications- Irma Kluijt
Family Cancer Clinic, The Netherlands Cancer Institute, Amsterdam, The Netherlands
8 shared publications - Cora M. Aalfs
Department of Clinical Genetics, Academic Medical Centre, Amsterdam, The Netherlands
7 shared publications
Latest Publications
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S362-S363
Sa1773 Factors Associated With Cancer Worries in Individuals Participating in Annual Pancreatic Cancer Surveillance
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S362-S363
Sa1773 Factors Associated With Cancer Worries in Individuals Participating in Annual Pancreatic Cancer Surveillance
- 25 May 2012
- Published by BMJ in Journal of Medical Genetics
- Vol. 49 (6) , 362-365
Indication for CDKN2A-mutation analysis in familial pancreatic cancer families without melanomas
Background: CDKN2A-mutation carriers run a high risk of developing melanomas and have an increased risk of developing pancreatic cancer (PC). Familial PC (FPC) patients with a personal history or family history of melanomas are therefore offered CDKN2A-mutation analysis. In contrast, CDKN2A testing in FPC families without a history of melanomas is not generally recommended. The aim of this study was to evaluate the frequency of CDKN2A-mutations in FPC families without melanomas. Methods: Data were gathered from PC family registers. FPC families were defined as families with clustering of PC without meeting diagnostic criteria of familial cutaneous malignant melanoma (familial CMM) or other inherited cancer syndromes. Blood samples were obtained for DNA isolation from PC patients or first degree relatives and analysed for CDKN2A-mutations. Results: Among 40 FPC families, DNA analyses were carried out in 28 families (70%), leading to identification of CDKN2A-mutations in six families (21%). None of the CDKN2A-mutation-positive families fulfilled the diagnostic criteria for familial CMM and in three CDKN2A families no melanomas were observed. Two CDKN2A-mutations were found; the Dutch founder mutation p16-Leiden (c.225_243del, p.Ala76fs) and the c.19_23dup, p.Ser8fs-mutation. After disclosure of the CDKN2A-mutation in one of the families, a curable melanoma was diagnosed at dermatological surveillance in a 17-year-old family member. Conclusion: CDKN2A-mutation can be found in a considerable proportion of families with FPC. CDKN2A-mutation analysis should therefore be included in genetic testing in FPC families, even in the absence of reported melanomas. This strategy will enhance the recognition of individuals at risk for PC and facilitate the early detection of melanomas.
- 25 May 2012
- Published by BMJ in Journal of Medical Genetics
- Vol. 49 (6) , 362-365
Indication for CDKN2A-mutation analysis in familial pancreatic cancer families without melanomas
Background: CDKN2A-mutation carriers run a high risk of developing melanomas and have an increased risk of developing pancreatic cancer (PC). Familial PC (FPC) patients with a personal history or family history of melanomas are therefore offered CDKN2A-mutation analysis. In contrast, CDKN2A testing in FPC families without a history of melanomas is not generally recommended. The aim of this study was to evaluate the frequency of CDKN2A-mutations in FPC families without melanomas. Methods: Data were gathered from PC family registers. FPC families were defined as families with clustering of PC without meeting diagnostic criteria of familial cutaneous malignant melanoma (familial CMM) or other inherited cancer syndromes. Blood samples were obtained for DNA isolation from PC patients or first degree relatives and analysed for CDKN2A-mutations. Results: Among 40 FPC families, DNA analyses were carried out in 28 families (70%), leading to identification of CDKN2A-mutations in six families (21%). None of the CDKN2A-mutation-positive families fulfilled the diagnostic criteria for familial CMM and in three CDKN2A families no melanomas were observed. Two CDKN2A-mutations were found; the Dutch founder mutation p16-Leiden (c.225_243del, p.Ala76fs) and the c.19_23dup, p.Ser8fs-mutation. After disclosure of the CDKN2A-mutation in one of the families, a curable melanoma was diagnosed at dermatological surveillance in a 17-year-old family member. Conclusion: CDKN2A-mutation can be found in a considerable proportion of families with FPC. CDKN2A-mutation analysis should therefore be included in genetic testing in FPC families, even in the absence of reported melanomas. This strategy will enhance the recognition of individuals at risk for PC and facilitate the early detection of melanomas.
- 1 May 2012
- Published by Elsevier in Gastroenterology
- Vol. 142 (5)
Mo1208 Pancreatic Cancer Risk in Peutz-Jeghers Patients; Results of a Large Dutch Cohort Study and Implications for Surveillance
- 1 May 2012
- Published by Elsevier in Gastroenterology
- Vol. 142 (5)
Mo1208 Pancreatic Cancer Risk in Peutz-Jeghers Patients; Results of a Large Dutch Cohort Study and Implications for Surveillance
- 1 May 2012
- Published by Elsevier in Gastroenterology
- Vol. 142 (5)
Su1816 Prospective Evaluation of Psychological Impact of Pancreatic Cancer Surveillance in High-Risk Individuals
- 1 May 2012
- Published by Elsevier in Gastroenterology
- Vol. 142 (5)
Su1816 Prospective Evaluation of Psychological Impact of Pancreatic Cancer Surveillance in High-Risk Individuals
- Open Access
- 14 December 2011
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 20 (5) , 577-579
Routine testing for PALB2 mutations in familial pancreatic cancer families and breast cancer families with pancreatic cancer is not indicated
PALB2-mutation carriers not only have an increased risk for breast cancer (BC) but also for pancreatic cancer (PC). Thus far, PALB2 mutations have been mainly found in PC patients from families affected by both PC and BC. As it is well known that the prevalence of gene mutations varies between different populations, we studied the prevalence of PALB2 mutations in a Dutch cohort of non-BRCA1/2 familial PC (FPC) families and in non-BRCA1/2 familial BC (FBC) families with at least one PC case. Mutation analysis included direct sequencing and multiplex ligation-dependent probe amplification (MLPA) and was performed in a total of 64 patients from 56 distinct families (28 FPC families, 28 FBC families). In total, 31 patients (48%) originated from FPC families; 24 were FPC patients (77%), 6 had a personal history of BC (19%) and 1 was a suspected carrier (3.2%). The remaining 33 patients (52%) were all female BC patients of whom 31 (94%) had a family history of PC and 2 (6.1%) had a personal history of PC. In none of these 64 patients a PALB2 mutation was found. Therefore, PALB2 does not have a major causal role in familial clustering of PC and BC in non-BRCA1/2 families in the Dutch population.
- 14 December 2011
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 20 (5) , 577-579
Open AccessRoutine testing for PALB2 mutations in familial pancreatic cancer families and breast cancer families with pancreatic cancer is not indicated
PALB2-mutation carriers not only have an increased risk for breast cancer (BC) but also for pancreatic cancer (PC). Thus far, PALB2 mutations have been mainly found in PC patients from families affected by both PC and BC. As it is well known that the prevalence of gene mutations varies between different populations, we studied the prevalence of PALB2 mutations in a Dutch cohort of non-BRCA1/2 familial PC (FPC) families and in non-BRCA1/2 familial BC (FBC) families with at least one PC case. Mutation analysis included direct sequencing and multiplex ligation-dependent probe amplification (MLPA) and was performed in a total of 64 patients from 56 distinct families (28 FPC families, 28 FBC families). In total, 31 patients (48%) originated from FPC families; 24 were FPC patients (77%), 6 had a personal history of BC (19%) and 1 was a suspected carrier (3.2%). The remaining 33 patients (52%) were all female BC patients of whom 31 (94%) had a family history of PC and 2 (6.1%) had a personal history of PC. In none of these 64 patients a PALB2 mutation was found. Therefore, PALB2 does not have a major causal role in familial clustering of PC and BC in non-BRCA1/2 families in the Dutch population.
- Open Access
- 1 May 2011
- Published by Elsevier in Gastroenterology
- Vol. 140 (5)
Indication for CDKN2A Mutation Analysis in Familial Pancreatic Cancer-Families Without Melanomas
- 1 May 2011
- Published by Elsevier in Gastroenterology
- Vol. 140 (5)
Open AccessIndication for CDKN2A Mutation Analysis in Familial Pancreatic Cancer-Families Without Melanomas
- 1 May 2011
- Published by Elsevier in Gastroenterology
- Vol. 140 (5)
Feasibility of a Pancreatic Cancer Surveillance Program From a Psychosocial Point of View
- 1 May 2011
- Published by Elsevier in Gastroenterology
- Vol. 140 (5)
Feasibility of a Pancreatic Cancer Surveillance Program From a Psychosocial Point of View